• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Medicare drug benefit could mean savings for patients with chronic conditions


Depending on the condition, average expected savings range from approximately $1,000 per year to more than $1,800 per year.

WASHINGTON, D.C.-Medicare beneficiaries with chronic conditions are likely to save money, perhaps a significant amount, if they enroll in the right Medicare Part D coverage plan, according to a recent report.

"This may not be the case for every Medicare beneficiary, but we encourage all potential enrollees to learn as much as they can about the new drug benefit and then make an informed decision," says Myrl Weinberg, president, National Health Council. The National Health Council released the report, "Savings from the Medicare Drug Benefit for Beneficiaries with Chronic Conditions," which consisted of an analysis of cost data from the Centers for Medicare and Medicaid Services conducted by The Lewin Group.

The scope of the study looked only at beneficiaries with common chronic conditions (Alzheimer's disease, arthritis, chronic obstructive pulmonary disease, diabetes, heart disease, hypertension, mental disorder, osteoporosis and Parkinson's disease) who face a decision whether to enroll in the Medicare drug benefit (i.e., excluding those automatically enrolled in the benefit and those with employer-based creditable drug coverage) and determine what impact the new Medicare prescription drug plan might have. The council's core membership comprises 50 national patient groups that collectively represent about 100 million people with chronic conditions and disabilities. Also included in this population are millions of Medicare beneficiaries. The study showed that:


Two other key pieces of information might be of interest to managed care executives, according to Weinberg.

"First, consider the large number of Medicare beneficiaries with one or more chronic conditions," she says. Eighty-six percent of the Medicare beneficiaries studied in the report had at least one chronic condition.

And second, Weinberg says, there is the potential to achieve greater compliance with treatment regimes within this population as medications become more affordable.

"Many Medicare beneficiaries decrease the dosages of their medications or stop taking them altogether because they cannot afford them," she says.


The proportion of elderly, chronically ill Medicare beneficiaries without supplemental private insurance that had problems affording prescription drugs rose from 12.4% to 16.4% between 2001 and 2003, according to the Community Tracking Study Household Survey, 2001 and 2003, cited in a May 2005 report published by the Center for Studying Health System Change.

"What this does is flood the healthcare system with people in need of emergency care for their chronic conditions and other types of acute care that could have been avoided and are ultimately more expensive than costs associated with consistent, ongoing care for patients with chronic conditions," Weinberg says.

"All chronic conditions should be viewed as important by the healthcare community," Weinberg says. "By investing now in consistent, comprehensive treatment, we can prolong health, improve quality of life and save money in the long term."

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.